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OBJECTIVES: This study compared the accuracy of the Simplified Acute Physiology Score 3 with that of Acute
Physiology and Chronic Health Evaluation II at predicting hospital mortality in patients from a transplant
intensive care unit.
METHOD: A total of 501 patients were enrolled in the study (152 liver transplants, 271 kidney transplants, 54
lung transplants, 24 kidney-pancreas transplants) between May 2006 and January 2007. The Simplified Acute
Physiology Score 3 was calculated using the global equation (customized for South America) and the Acute
Physiology and Chronic Health Evaluation II score; the scores were calculated within 24 hours of admission. A
receiver-operating characteristic curve was generated, and the area under the receiver-operating characteristic
curve was calculated to identify the patients at the greatest risk of death according to Simplified Acute
Physiology Score 3 and Acute Physiology and Chronic Health Evaluation II scores. The Hosmer-Lemeshow
goodness-of-fit test was used for statistically significant results and indicated a difference in performance over
deciles. The standardized mortality ratio was used to estimate the overall model performance.
RESULTS: The ability of both scores to predict hospital mortality was poor in the liver and renal transplant
groups and average in the lung transplant group (area under the receiver-operating characteristic curve = 0.696
for Simplified Acute Physiology Score 3 and 0.670 for Acute Physiology and Chronic Health Evaluation II). The
calibration of both scores was poor, even after customizing the Simplified Acute Physiology Score 3 score for
South America.
CONCLUSIONS: The low predictive accuracy of the Simplified Acute Physiology Score 3 and Acute Physiology
and Chronic Health Evaluation II scores does not warrant the use of these scores in critically ill transplant
patients.
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& INTRODUCTION
Scoring systems, which predict patient outcomes in
intensive care units, have been studied for more than three
decades. The performance of prognostic models encom-
passes two objective measurements: discrimination (the
model’s ability to classify survivors and non-survivors) and
calibration (agreement between the observed and expected
numbers of survivors and non-survivors) (1-8).
Acute Physiology and Chronic Health Evaluation
(APACHE) scores and Simplified Acute Physiology Score
(SAPS) models were previously validated as severity
scoring systems. However, several groups were not well
represented in the databases that were used to validate
these prognostic systems, including transplant patients.
The validation of APACHE II included only 47 kidney
transplant patients, without any lung or liver transplant
recipients (9). The validation of APACHE III, a further
update, involved 17,440 patients but included only 40 liver
transplant patients; lung and kidney transplant patients
were absent (10). The validation of SAPS 3 included 172
transplant patients: 90 liver, 55 kidney, eight lung, five
kidney-pancreas, three pancreas and 11 cardiac transplant
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patients (11,12). For the validation of APACHE IV, 224
kidney and 139 liver transplant patients were enrolled, but
no lung transplant patients were included (13).
SAPS 3 evaluates the data obtained during the first hour
of intensive care unit (ICU) admission, which is useful for
assessing a patient’s condition upon arrival and eliminating
the factors attributable to the level of the care unit. With
these adjustments, there have been improvements in the
prediction of early and late mortality, as well as increased
score sensitivity.
We chose to validate the APACHE II scoring system
instead of the APACHE IV because the former has been
extensively used to assess severity of illness in transplant
patients (14-16). However, to our knowledge, there have
been no studies applying SAPS 3 specifically to transplant
patients or comparing the predictive accuracy of the two
scores in this patient group.
The objective of the present study was to compare the
accuracy of SAPS 3 with that of APACHE II in predicting in-
hospital mortality in patients from a transplant ICU.
& MATERIALS AND METHODS
Study design
This was a prospective clinical cohort study conducted in
an 11-bed transplant ICU in southern Brazil (Dom Vicente
Scherer Hospital, Complexo Hospitalar da Santa Casa de
Porto Alegre). All of the patients receiving cadaver donor
organs and admitted to the ICU between May 2006 and
January 2007 were enrolled.
Patients
Patients aged $18-years after their first transplant were
included in the study during the early postoperative period
(,24 hours). Retransplant and living donor transplant
patients were excluded.
Ethics
This study was approved by the Research Ethics
Committee of the institution and was conducted in
accordance with the provisions of the Declaration of
Helsinki. All of the participants or their family members
signed informed consent forms. The data were collected and
recorded by a single author.
Assessments
The first ICU admission for each patient was used to
predict hospital mortality. The APACHE II score was
calculated in the first 24 hours after ICU admission, and
the SAPS 3 score was calculated within 1 hour of admission
(11,12).
The adjusted probability of death, according to the
diagnostic category of APACHE II, was also calculated (9).
The probability of in-hospital death for SAPS 3 was
calculated according to the general equation and was
customized for South America. Customization has been
more accurate in predicting the mortality of oncological
patients admitted to ICUs in Brazil (11,12,17,18).
Statistical analysis
The data were analyzed using the Statistical Package for
the Social Sciences (SPSS), version 13.0 for Windows (SPSS
Inc. Chicago, IL, USA). Receiver-operating characteristic
(ROC) curves were generated for the SAPS 3 and APACHE
II scores to assess the predictive accuracy of these models
and to determine the in-hospital mortality for each type of
transplant (19).
To assess discrimination (capacity to classify survivors
and non-survivors), sensitivity and specificity were calcu-
lated for the different SAPS 3 and APACHE II scores by
plotting the ROC curve and calculating the respective area
under the curve.
The best discriminating value was determined by max-
imal sensitivity and specificity. The highest value that
resulted from this product was used as the cutoff point, and
95% confidence intervals (95% CIs) were computed for true-
and false-positive rates and for the correct classification rate
of the outcomes.
The Hosmer-Lemeshow goodness-of-fit test was used to
assess calibration (the agreement between the observed and
expected numbers of survivors and non-survivors with
regard to the probability of death) (20). In this analysis,
p.0.05 was believed to indicate good test adjustment.
The standardized mortality ratio (SMR) was calculated by
dividing the observed mortality rate by the predicted
mortality rate. An SMR equal to 1.0 indicated that the
number of observed deaths equaled that of the expected
number of deaths; an SMR.1.0 indicated the occurrence of
a greater number of deaths than expected. Calibration and
discrimination were assessed (as previously described) for
the original models.
& RESULTS
The study included 501 postoperative transplant patients
admitted to the ICU between May 2006 and January 2007.
The mean patient age was 46¡2 years old; extubation
occurred within 24 hours of admission (institutional proto-
col); the median ICU stay was three days (25th, 50th, and
75th percentiles of two, three, and five days, respectively),
and the median hospital stay was 21 days (25th, 50th, and
75th percentiles of 14, 21, and 35 days, respectively).
The sample included 152 (30%) liver transplant patients
(116 male, 36 female), 271 (54.9%) kidney transplant patients
(168 male, 103 female), 54 (10.7%) lung transplant patients
(29 male, 25 female), and 24 (4.7%) kidney-pancreas
transplant patients (15 male, 9 female).
The ranges of the APACHE II and SAPS 3 scores among
survivors and non-survivors are shown in Table 1.
APACHE II significantly overestimated the mortality
rates for all of the transplant patients. An analysis by type
of transplant showed that the score underestimated the
mortality rate in lung transplant patients, which was 52%
greater than the predicted rate, with no statistical signifi-
cance. In the other cases, the score overestimated mortality
non-significantly, except for renal transplant patients
(Table 2).
The SAPS 3 global equation underestimated the mortality
rate in all types of transplants and showed statistical
significance in cases of renal and pulmonary transplants
(Table 2). The same poor performance was observed after
customizing for South America, underestimating mortality
in all of the groups and underestimating it statistically
significantly in the same groups, as with the SAPS 3 global
equation (Table 2).
For score calibration, the Hosmer-Lemeshow (HL-H and
HL-C) tests were applied to all transplant groups; the test
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showed performance differences and overestimated the
deciles for both scores (Table 3).
For score discrimination, an ROC curve analysis was used
(Figure 1). Mortality discrimination was poor in the scores
for both the liver and renal transplant groups and was
average for the lung transplant group. The kidney-pancreas
sample was too small for analysis.
ROC curve analysis indicated a cutoff point above which
the discrimination to predict mortality increased significantly
for each group. For the liver transplant patients, SAPS 3$40
had sensitivity of 0.6 and specificity of 0.46 in predicting
mortality, whereas APACHE II$16.5 had sensitivity of 0.67
and specificity of 0.63. In the lung transplant group, SAPS
3$31.5 had sensitivity of 0.69 and specificity of 0.73 in
predicting mortality, whereas the sensitivity and specificity
of APACHE II$17.5 were 0.69 and 0.76, respectively.
& DISCUSSION
In the present study, no differences were observed
between SAPS 3 and APACHE II scores regarding their
ability to predict hospital mortality in the transplant groups
analyzed, even after customizing for South America. A
study by Silva Junior et al. showed accuracy in predicting
mortality with the South America-customized SAPS 3
equation in two surgical ICUs in Brazil (21). Their results
did not match those of this study, most likely because
transplant patients present a different surgical profile from
that of general ICU patients; therefore, the two patients
cohorts should be studied separately.
In terms of hospital mortality, the discrimination of both
scores was poor for the liver and kidney transplant groups
and average for the lung transplant group. Both score
calibrations were poor for all of the groups.
These results are consistent with the literature, in which
some studies have previously reported that SAPS models
and APACHE scores are likely to overestimate mortality in
high-risk patients and underestimate mortality in low-risk
patients (2,8).
Liver transplant group
The mortality of our liver transplant patients was over-
estimated by APACHE II. Several studies that used the
APACHE system in liver transplants have shown opposite
results. Spanier et al. (23) used APACHE II to assess 102
patients with end-stage liver disease awaiting transplanta-
tion; the authors reported low accuracy of this score for
predicting the risk of death. Bein et al. (24) and Sawyer et al.
(25) reported a correlation between mortality and APACHE
II scores, but predicted mortality was not calculated in
either study (25).
Angus et al. (26) used APACHE II in a group of liver
transplant patients and concluded that the score was a good
predictor of long-term (1-year) mortality after liver trans-
plantation. An attempt to calibrate APACHE II for post-
operative liver transplant patients (25-28) resulted in the
overestimation of mortality, although to a lesser degree
when compared with the original model. Arabi et al. (27)
used the recalibration of APACHE II proposed by Angus
et al. (26), and the results were the same as those obtained in
the study by the latter group.
Keegan et al. (30) evaluated the performance of APACHE
III in liver transplant recipients and demonstrated poor
performance.
Recently, Park et al. (29) applied APACHE II and
APACHE III scores in urgent liver transplant patients with
acute liver failure. There was weak mortality prediction in
this patient group, with mean scores (survivors 22.50¡5.89
and non-survivors 18.19¡5.89) and areas under the ROC
curve (0.713 and 0.737 with p,0.05) that were similar to
those found in our study.
No studies have reported results using SAPS 3 scores in
liver transplant patients.
Kidney transplant group
Mortality was also overestimated by APACHE II in our
kidney transplant patients. Past evidence has indicated that
APACHE II was not adequate for evaluating mortality in
this group (25,33).
Table 1 - Survivors and non-survivors according to APACHE II and SAPS 3 scores: mean values (¡SD) and hospital
mortality obtained in the different transplant patient groups.
APACHE II Mean¡SD
Survivors (n)
APACHE II Mean¡SD
Non-survivors (n) p-value
SAPS 3 Mean¡SD
Survivors (n)
SAPS 3 Mean¡SD
Non-survivors (n) p-value
Liver 15.8¡5.2 (n = 134) 19.5¡6.1 (n= 18) p,0.07 41.2¡8.3 (n = 134) 47.3¡14.9 (n= 18) p,0.107
Kidney 17.1¡3.5 (n = 264) 19.86¡8.59 (n= 7) p,0.42 21.8¡6.20 (n = 264) 21.71¡7.71 (n= 7) p,0.958
Lung 16.02¡3.70 (n = 41) 21.77¡5.77 (n= 13) p,0.04 27.46¡5.90 (n = 41) 35.08¡8.07 (n= 13) p,0.01
Kidney-pancreas 15.70¡4.41 (n = 24) 24¡0.91 (n= 1) p,0.79 25.09¡7.26 (n = 24) 22¡1.51 (n= 1) p,0.682
SD= standard deviation; APACHE II =Acute Physiology and Chronic Health Evaluation; SAPS 3= Simplified Acute Physiology Score models.
Table 2 - Relationship between observed and predicted mortality rates within each group according to the SAPS 3
global equation, South America customized equation and APACHE II.
Transplant Type n
Observed
Mortality
n (%)
APACHE II
Predicted
Mortality
n (%)
SMR
(ESTIMATE)
95% CI
SAPS 3 Global
Equation
Predicted
Mortality n (%)
SMR
(ESTIMATE)
95% CI
SAPS 3
America Do Sul
Equation n (%)
SMR
(ESTIMATE)
95% CI
Liver 152 18 (11.8) 22 (14.69) 0.81 16 (10.69) 1.11 (0.66-1.75) 16 (10.62) 1.12 (0.66-1.76)
Kidney 271 7 (2.6) 40 (14.77) 0.17 2 (0.76) 3.42 (1.37-7.04) 3 (0.97) 2.67 (1.07-5.50)
Lung 54 13 (24.1) 9 (15.87) 1.52 1 (2.61) 9.22 (4.90-15.77) 2 (2.90) 8.31 (4.42-14.21)
Kidney-Pancreas 24 1 (4.2) 3 (12.88) 0.32 1 (1.63) 2.56 (0.06-14.28) 1 (1.71) 2.44 (0.06-13.57)
TOTAL 501 39 (7.8) 74 (14.77) 0.53 20 (4.01) 1,94 (1.38-2.64) 21 (4.14) 1.88 (1.34-2.56)
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No previous studies reporting the use of SAPS 3 in kidney
transplant patients were available for a comparison with our
findings.
We believe that some admission variables applied to
SAPS 3 scores, such as creatinine, mechanic ventilation and
the need for kidney repositioning, are not predictors of
death (36); this belief may explain the overestimation of
mortality in this group.
Lung transplant group
Slightly better performance was observed for APACHE II
and SAPS 3 in lung transplant patients. However, these
Figure 1 - ROC curve for APACHE II and SAPS 3: a) all types of transplantations; b) liver transplantations; a) All types of transplantations.
SAPS 3 AUROC 0.696 95%CI (0.607-0.786) APACHE II AUROC 0.670 95%CI (0.579-0.762) P=0.670*. b) Liver transplantations. SAPS 3
AUROC 0.612 95%CI (0.450-0.733).
Table 3 - The Hosmer-Lemeshow (HL-H and HL-C) tests applied to all transplant groups.
H-L C-statistics (DF= 8) H-L H- statistics (DF = 6) AUROC (95% CI)
X2 p-value X2 p-value p-value
SAPS3 155.57 ,0.001 59.41 ,0.001 0.696 (0.607-0.786) 0.670
APACHE II 43.72 ,0.001 44.37 ,0.001 0.670 (0.579-0.762) 0.670
AUROC = area under the curve; DF = degree of freedom; HL-H and HL-C = Hosmer-Lemeshow tests X2 = chi-squared; APACHE II =Acute Physiology and
Chronic Health Evaluation; SAPS 3= Simplified Acute Physiology Score models.
SAPS 3 or APACHE II to predict mortality
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results cannot be compared with those of previous studies
because there have been no reports in the literature
regarding the application of APACHE II disease severity
scores in this specific group. In validation studies focused
on mortality scores, only SAPS 3 was used with this patient
group (in small numbers) (11,12).
Some important advantages of this study included the
short data collection period, the prevention of possible
biases resulting from medical and technological improve-
ments that occurred during the study period, and the fact
that all of the transplant patients came from a single service
that used standardized clinical and surgical methods and
techniques.
The present results should be interpreted carefully. Our
study had a number of limitations. The patients were cared
for at a single center and thus might not be representative of
other ICUs in other medical centers. While this fact reflects
the referral practice of our institution, it might limit the
generalization of our findings.
However, the validation of SAPS 3 in a group of patients
at a single center might more accurately reflect the model
performance, without the confounding influence of differ-
ing standards of care at different institutions.
In contrast, the low number of deaths limited the power
of the calibration analysis.
We believe that the low accuracy of SAPS 3 and APACHE
II in transplant patients stems from these systems under-
scoring physiologic aspects, such as creatinine level and
liver function, which are usually (and by definition) poor in
transplant patients before they receive new organs and can
persist into the immediate postoperative period (28).
However, because these variables tended to improve
rapidly following transplantation, the scores overestimated
mortality in the end.
Our results clearly demonstrate the need for a severity of
illness classification system that specifically focuses on
transplant patients, as well as on patient subgroups
receiving different types of transplants.
Although this transplant sample was sufficiently large to
assess illness severity scores, it was still too small for the
design of a new predictive model. In addition, the results
described here refer to one single ICU located in one specific
country and region.
We recommend using different scores that consider each
transplant’s peculiar characteristics that contribute to post-
transplantation mortality, such as MELD score variables for
liver transplant patients (27-30), which account for creati-
nine, prothrombin time (INR) and bilirubin. For example,
SAPS3 does not consider prothrombin time, a liver function
marker that is an important variable. Studies that used
MELD to predict post-liver transplant survival have shown
conflicting results (31-35). These results could have been
affected by using only pre-operative variables, thereby
neglecting perioperative variables, such as surgical techni-
que, ischemic time, graft conditions, and the need for
immunoglobulin.
The Lung Allocation Score (LAS) has demonstrated great
accuracy in predicting short-term mortality increases,
survival decreases and increases in complications in the
first year after lung transplants (34-36). Although this score
was not developed for lung transplant patients, using some
of its variables could influence the results in this patient
group.
Therefore, a combination of variables from SAPS 3 (post-
operatory) and LAS (pre-operatory) and other perioperative
factors might help to define a better score for use in this
specific subgroup.
Finally, to the authors’ knowledge, this was the first study
using SAPS 3 in transplant patients to demonstrate that this
score did not predict hospital mortality in this population.
The present findings indicate that the accuracy of SAPS 3 is
as low poor as that of APACHE II in predicting in-hospital
mortality in postoperative transplant patients who are
admitted to the ICU and overestimated patient mortality.
The poor discrimination and calibration obtained with SAPS
3 and APACHE II do not warrant the use of these scoring
systems in this patient group.
The lack of any similar studies precluded a comparison of
our results with those of other researchers. Further studies
will be necessary to validate our results.
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